Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research | Suppliers

reMYND - Alzheimer in vivo CRO White Papers

reMYND - Alzheimer in vivo CRO

reMYND’s APP-London model and its bigenic combination with PS1[A246E] reMYND's APP[V717I] and APP[V717I] x PS1[A246E] transgenic amyloidopathy mouse models – biochemical and immunohistochemical characterization.
View white paper
reMYND’s TAU[P301L] model and its bigenic combination with APP-London reMYND’s TAU[P301L] transgenic tauopathy mouse model – biochemical and immunohistochemical characterization.
View white paper
Concise overview presentation of reMYND’s Contract Research Offering As experts in compound testing in highly validated, proprietary Alzheimer transgenic mice, we can offer you an extensive scope of in-vivo testing and ample support in study design and data interpretation.
View white paper
One-page brochure of reMYND’s CRO Helping you understand the therapeutic in vivo effects of your Alzheimer drug candidates.
View white paper
Review paper discussing the pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer’s disease of the APP[V717I] London transgenic mouse model; also touching on reMYND’s other proprietary transgenic mouse models (Tanghe et al., 2010). Notwithstanding the vast amount of resources invested into discovery and development of new targets and treatments, Alzheimer’s disease (AD) remains an indication with enormous unmet needs. One complicating factor for successful drug development is the unknown etiology of idiopathic AD. AD entails noxious aggregation of β-amyloid (Abeta) and Tau, representing fundamental processes in disease onset and progression
View white paper